IKCS 2020: Treatment selection in kidney cancer

During this interview, Dr Rana McKay from the University of California in San Diego gives a succinct overview of the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020), including highlights from the meeting. She also discussed the effects of delaying surgery for patients with low stage (T1 and T2) renal cell carcinoma […]

read more

Stereotactic radiation for the treatment of kidney cancer

This paper reviews the use of stereotactic body radiotherapy (SBRT) for the treatment of renal cell carcinoma (RCC), and was presented at the Society of Urologic Oncology (SUO) in Washington last week. In conclusion: RCC is radiosensitive and SBRT can be used to stabilise or manage the symptoms of primary tumours SBRT may be useful […]

read more

ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

Results from the SORCE clinical trial to assess sorfenib as an adjuvant treatment for renal cell carcinoma (RCC) at intermediate or high risk of relapse were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. As for previous large randomised phase 3 clinical trials (ASSURE, PROTECT, and ATLAS) to […]

read more

ASCO 2019: Effectiveness of pazopanib after kidney cancer metastasectomy

In this phase III study, presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, the use of treatment with pazopanib after surgery to remove renal cell carcinoma (RCC) metastases (metastasectomy) was investigated. One hundred and twenty-nine patients with no evidence of disease after surgery to remove RCC metastases […]

read more

A review of adjuvant therapy options for kidney cancer

In this paper, published in Current Treatment Options in Oncology last month, the authors review the recent randomised controlled clinical trials looking at the use of post-surgery (adjuvant) vascular endothelial growth factor (VEGF) inhibitors for the treatment of renal cell carcinoma (RCC) that has not spread. The authors recommend, based on current data, that adjuvant […]

read more

Lymph node dissection identifies patients at high risk of kidney cancer spread

A recent study published in the journal Science Direct suggests that lymph node dissection (lymphadenectomy) in patients with non-metastatic renal cell carcinoma (RCC) at high risk of recurrence/spread could be used to identify patients who are most likely to benefit from adjuvant therapy. In the study, the researchers retrospectively assessed the progression of the disease in […]

read more

ESOU 2019: Adjuvant therapy after nephrectomy for high-risk renal cell carcinoma

The following presentations were given at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. The first presentation approached the discussion of adjuvant therapy after nephrectomy for high-risk renal cell carcinoma (RCC) from a urologist’s perspective, while the second presentation presents the oncologist’s perspective. Read the urologist’s perspective […]

read more

MD Anderson Cancer Center 13th Update on the Management of Genitourinary Malignancies Conference

The MD Anderson Cancer Center (MDACC) 13th Update on the Management of Genitourinary Malignancies Conference took place in Houston, Texas at the end of last week (9-10 November). Kidney cancer highlights from the meeting have been published by UroToday. You can read more online on UroToday below: MDACC 2018: Promising Emerging Systemic Therapies for mRCC MDACC […]

read more

ESMO 2018: Interviews with the kidney cancer experts

The following video interviews with kidney cancer experts from the USA and Europe were conducted at the recent European Society of Medical Oncology (ESMO) 2018 congress in Munich last month. The interviews cover topics such as a new treatment for VHL-associated kidney cancer, real world effectiveness of pazopanib for renal cell carcinoma (RCC), recommendations for […]

read more

ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance

Results from the latest adjuvant study with a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), axitinib (Inlyta), were presented at the European Society of Medical Oncology (ESMO) 2018 conference in Munich over the weekend. Results of clinical trials assessing adjuvant therapy for intermediate- and high-risk renal cell carcinoma (RCC) with VEGF TKIs have […]

read more
Showing 1 to 10 of 33 results
  TOP